Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival

• Published in: Cancers Vol. 16; no. 8; p. 1484
• Main Authors: Aarstad, Helene Hersvik, Moe, Svein Erik Emblem, Lybak, Stein, Bruserud, Øystein, Tvedt, Tor Henrik Anderson, Aarstad, Hans Jørgen
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12.04.2024
• Subjects: Adenomatous polyposis coli; Cancer therapies; Cytokine receptors; Cytokines; Diagnosis; Glycoprotein gp130; Head & neck cancer; Head and neck carcinoma; Human papillomavirus; Immunotherapy; Inflammation; Interleukin 1; Interleukin 1 receptor antagonist; Interleukin 1 receptors; Interleukin 6; Patients; Plasma; Plasma levels; Smoking; Squamous cell carcinoma; United States > US; Norway; gp130; TNM stage; IL-6; HPV; IL-31; head and neck squamous cell carcinoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16081484

Activation of the acute-phase cascade (APC) has been correlated with outcomes in various cancers, including head and neck squamous cell carcinoma (HNSCC). Primary drivers of the APC are the cytokines within the interleukin-6 (IL-6) and IL-1 families. Plasma levels of IL-6 family cytokines/soluble receptors (IL-6, IL-27, IL-31, OSM, CNTF, soluble (s-)gp130, s-IL-6Rα) and IL-1 family members (IL-1RA, s-IL-33Rα) were determined at diagnosis for 87 human papillomavirus (HPV)-negative (-) HNSCC patients. We then studied the 5-year Disease-Specific Survival (DSS) and Overall Survival (OS). Increased plasma levels of IL-6 ( < 0.001/ < 0.001) (DSS/OS), IL-31 ( = 0.044/ = 0.07), IL-1RA ( = 0.004/ = 0.035), soluble (s)-IL-6Rα = 0.022/ = 0.035), and s-gp130 ( = 0.007/ = 0.003) at diagnosis were predictors of both OS and DSS from HPV(-) HNSCC patients. The cytokine DSS/OS predictions were associated with TNM stage and smoking history, whereas the soluble receptors IL-6Rα, gp130, and IL33Rα more uniquely predicted DSS/OS. Clinically, IL-6 levels above 2.5 pg/mL yielded 75% specificity and 70% sensitivity for DSS. In conclusion, high plasma levels of IL-6, IL-31, and IL-1RA, as well as the soluble receptors IL-6Rα, gp130, and IL33Rα, predicted clinical outcome. This shows their potential as candidates for both general therapy and immune therapy stratification, as well as being future platforms for the development of new immunotherapy.